The investment “represents the single largest investment in synthetic medicine [active pharmaceutical ingredient] manufacturing in U.S. history,” Eli Lilly’s chair and CEO David Ricks said in a news release.
Leaders of the manufacturing sites in Lebanon, Ind., will hire 200 full-time workers to help increase production. Mounjaro is approved for Type 2 diabetes and Zepbound is indicated for chronic weight management. Eli Lilly is also eyeing a Zepbound label expansion after finding positive results in a sleep apnea trial.
The announcement raises the company’s total investment in the Lebanon site from $3.7 billion to $9 billion.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
